Silexion Therapeutics (SLXN) was 74% higher in Wednesday's after-hours session, after it disclosed preclinical data demonstrated the synergistic efficacy of its SIL-204 candidate to treat certain form of pancreatic cancer.
The data show that SIL-204 worked well in combination with the primary components of two chemotherapies, 5-fluorouracil and irinotecan, in human cell lines containing pancreatic cancer with KRAS G12D mutations, the most common form of the disease. SIL-204 also showed synergistic activity with gemcitabine, another chemotherapeutic agent, Silexion said.
The company currently is preparing SIL-204 for upcoming clinical trials, with toxicology studies set to begin within a few months and phase 2/3 testing planned for H1 2026, beginning with locally advanced pancreatic cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.